MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players
As part of Protisvalor, the research transfer subsidiary of Aix-Marseille University, I have accompanied researchers from the University for nearly 4 years, first to identify European funding opportunities to meet their needs and then to help them develop proposals for submission to the European Commission. As an immunologist, I have participated in all stages of the innovation chain of Marseille Immunopôle, from research to industry and technology transfer. I have always followed R&D projects with particular interest on collaborative projects focused on immunology, involving both scientists, clinicians and industrials.
MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players. MI will make us more visible and efficient. Together, we have the unique opportunity to make Marseille metropolis a global hub for fundamental and applied immunology and a capital for immunotherapy R&D. Being involved in this very ambitious project is a privilege and a real responsibility!#ecosystème
Thanks to this unprecedented alliance of researchers, clinicians, technological platforms and industrials we should be able to quickly do much better
Today Marseille Immunopôle is a great opportunity to challenge our discipline with novel perspectives.
AMU, IPC, CRCM
Marseille Immunopole should allow us now to accelerate the development of therapeutic antibodies, the new drugs that are changing the course of cancer treatment.
AMU, IPC, CRCM
Immunotherapy is expanding to other cancers types: kidney cancer, bladder cancer, hepatocellular carcinoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma… but we are still only at the beginning of the story!